Eupraxia’s EoE Drug Delivers Consistent Results at 52 Weeks
At 52 weeks, 2 of 3 patients in Cohort 6 of Eupraxia’s RESOLVE trial remained in clinical remission on...
Celcuity Submits New Breast Cancer Drug Application to FDA
The Phase 3 VIKTORIA-1 PIK3CA wild-type cohort reported a hazard ratio of 0.24 for the gedatolisib triplet (gedatolisib, fulvestrant,...
Pasithea’s NF1 Drug PAS-004 Shows Positive PK Data in Trial
PAS-004’s new tablet showed linear, dose-proportional PK with a long half-life (~57 hours) and tight peak–trough control at steady...
New Data Highlights Zio Performance in an Asian Population
In a real-world analysis of 408,470 U.S. patients monitored with iRhythm’s Zio long-term continuous ECG service, median wear time...
Annovis Links Amyloid to Faster Decline in Parkinson’s
Annovis reported that in its Phase 3 study in early Parkinson’s disease (NCT05357989), buntanetap halted cognitive decline across the...
Eledon Reports Preliminary Tegoprubart Data in Diabetes Trial
In an investigator-initiated islet transplant study in type 1 diabetes, 6 of 6 patients achieved insulin independence on a...
Promising New Padeliporfin Phase 3 Data for UTUC Revealed
Padeliporfin vascular targeted photodynamic therapy produced a 73% complete response rate (27 of 37 evaluable patients) with a generally...
FDA Approves Eylea HD for RVO and Macular Edema Treatment
In the Phase 3 QUASAR trial, EYLEA HD (aflibercept 8 mg) dosed every eight weeks after either three or...
TLX250-CDX Impacts Decisions for Indeterminate Renal Masses
In a post-hoc analysis of 294 patients with indeterminate renal masses, TLX250-CDx (89Zr-DFO-girentuximab) PET/CT would have changed clinical management...
Promising Diabetic Ulcer Treatment Enters Clinical Trial
FibroBiologics will enroll 120 patients across 10 Australian sites in a randomized Phase 1/2 trial of CYWC628, a topically...